Azacytidine for Angioblastic T-cell lymphoma
. NCCN lists azacytidine a 2nd line treatment for a similar T-cell peripheral lymphoma. Unfortunately, NCCN does nto provide a guidelines for angiblastic T-cell lymphoma, which is rare. However, literature suggests that it si also effective in this subtype.
François Lemonnier, Jehan Dupuis, Pierre Sujobert, Olivier Tournillhac, Morgane Cheminant, Clémentine Sarkozy, Laura Pelletier, Ambroise Marçais, Cyrielle Robe, Virginie Fataccioli, Corinne Haioun, Olivier Hermine, Philippe Gaulard, Richard Delarue, Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood (2018) 132 (21): 2305–2309.
Laribi K, Baugier de Materre A, Touileb Y, Boursot C, Sandrini J, Cavalieri D, Pastoret C, de Leval L, Tournilhac O. Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma. Hemasphere. 2022 Feb 1;6(2):e675.
Gregory GP, Dickinson M, Yannakou CK, Wong J, Blombery P, Corboy G, Kats L, Crozier TME, Kumar B, Prince HM, Opat SS, Shortt J. Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS. Hemasphere. 2019 Mar 1;3(2):e187.
NCCN PTCEL-B,4 2024